Payment overview · 2025
General Payments
$87.56
4 reported records · 2 companies
Healthcare provider profile · identity verified
Shamim Ahmed, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WOODSIDE, NY · NPI 1003839655
Verified facts
What the public records show
CMS Open Payments records show Shamim Ahmed, MD received $87.56 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 69.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.89 | 69.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.67 | 30.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $87.56 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $42.14 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
179 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1060 | 365 |
| Losartan Potassium | Losartan Potassium | 690 | 224 |
| Amlodipine Besylate | Amlodipine Besylate | 631 | 224 |
| Famotidine | Famotidine | 520 | 177 |
| Metformin Hcl | Metformin Hcl | 514 | 183 |
| Jardiance | Empagliflozin | 502 | 116 |
| Omeprazole | Omeprazole | 455 | 157 |
| Metoprolol Succinate | Metoprolol Succinate | 438 | 151 |
| Gabapentin | Gabapentin | 350 | 122 |
| Tamsulosin Hcl | Tamsulosin Hcl | 334 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 319 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 292 | 99 |
| Simvastatin | Simvastatin | 220 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 73 |
| Montelukast Sodium | Montelukast Sodium | 188 | 63 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 185 | 42 |
| Alendronate Sodium | Alendronate Sodium | 184 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 70 |
| Farxiga | Dapagliflozin Propanediol | 179 | 50 |
| Januvia | Sitagliptin Phosphate | 160 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 155 | 88 |
| Lisinopril | Lisinopril | 153 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 48 |
| Glimepiride | Glimepiride | 148 | 54 |
| Nifedipine Er | Nifedipine | 135 | 43 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 134 | 39 |
| Ozempic | Semaglutide | 130 | 32 |
| Finasteride | Finasteride | 120 | 37 |
| Metformin Hcl Er | Metformin Hcl | 117 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 42 |
| Mirtazapine | Mirtazapine | 107 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 35 |
| Novolog Flexpen | Insulin Aspart | 100 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 95 | 55 |
| Atenolol | Atenolol | 94 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 52 |
| Furosemide | Furosemide | 87 | 33 |
| Repaglinide | Repaglinide | 87 | 33 |
| Valsartan | Valsartan | 85 | 28 |
| Donepezil Hcl | Donepezil Hcl | 82 | 29 |
| Eliquis | Apixaban | 81 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 80 | 50 |
| Carvedilol | Carvedilol | 79 | 28 |
| Allopurinol | Allopurinol | 78 | 26 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 77 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 28 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 73 | 34 |
| Ammonium Lactate | Ammonium Lactate | 72 | 40 |
| Glipizide Er | Glipizide | 67 | 23 |
| Meloxicam | Meloxicam | 67 | 49 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 66 | 33 |
| Nortriptyline Hcl | Nortriptyline Hcl | 58 | 20 |
| Memantine Hcl | Memantine Hcl | 56 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 24 |
| Meclizine Hcl | Meclizine Hcl | 52 | 30 |
| Azelastine Hcl | Azelastine Hcl | 48 | 37 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 15 |
| Glipizide | Glipizide | 46 | 11 |
| Trulicity | Dulaglutide | 46 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 45 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 13 |
| Sertraline Hcl | Sertraline Hcl | 45 | 14 |
| Tradjenta | Linagliptin | 44 | 16 |
| Fenofibrate | Fenofibrate | 42 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 26 |
| Linzess | Linaclotide | 41 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 13 |
| Labetalol Hcl | Labetalol Hcl | 40 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 28 |
| Ranolazine Er | Ranolazine | 38 | 14 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 35 | 28 |
| Terazosin Hcl | Terazosin Hcl | 34 | 11 |
| Trazodone Hcl | Trazodone Hcl | 32 | 12 |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 15 |
| Folic Acid | Folic Acid | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 29 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 20 |
| Halobetasol Propionate | Halobetasol Propionate | 27 | 18 |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Prednisone | Prednisone | 25 | 11 |
| Pregabalin | Pregabalin | 24 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | 15 |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 24 | 15 |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | 15 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | 12 |
| Ibuprofen | Ibuprofen | 21 | 18 |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | 11 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | 12 |
| Ramipril | Ramipril | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 13 |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Abacavir | Abacavir Sulfate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lamivudine Hbv | Lamivudine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tivicay | Dolutegravir Sodium | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $87.56 · 4 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Kerendia | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error